Dose escalation trial of cyclophosphamide with sargramostim in the treatment of central nervous system (CNS) neoplasms

Daniel H. Lachance; Dagmar Oette; S. Clifford Schold; Mark Brown; Joanne Kurtzberg; Michael L. Graham; Robert Tien; Gary Felsberg; O. Michael Colvin; Albert Moghrabi; Iley Browning; Beverly Hockenberger; Elizabeth Stewart; Lee Ferrell; Tracy Kerby; Margaret Duncan‐Brown; Barry Golembe; Herb Fuchs; Ruth Fredericks; Frances Ann Hayes; Abbe Sue Rubin; Darell D. Bigner; Henry S. Friedman

doi:10.1002/mpo.2950240406

Dose escalation trial of cyclophosphamide with sargramostim in the treatment of central nervous system (CNS) neoplasms

Daniel H. Lachance, Dagmar Oette, S. Clifford Schold, Mark Brown, Joanne Kurtzberg, Michael L. Graham, Robert Tien, Gary Felsberg, O. Michael Colvin, Albert Moghrabi, Iley Browning, Beverly Hockenberger, Elizabeth Stewart, Lee Ferrell, Tracy Kerby, Margaret Duncan‐Brown, Barry Golembe, Herb Fuchs, Ruth Fredericks, Frances Ann HayesAbbe Sue Rubin, Darell D. Bigner, Henry S. Friedman

Neurology

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

We conducted a dose escalation trial of cyclophosphamide plus Sargramostim in the therapy of patients with newly diagnosed or recurrent central nervous system tumors. Cyclophosphamide was administered at doses ranging between 1.0 and 2.5 g/m² daily for two doses. Sargramostim was administered at a fixed dose of 250 μg/m² subcutaneously twice a day beginning 24 hours after the second cyclophosphamide dose and continuing through the leukocyte nadir until the absolute neutrophil count (ANC) was >1,000 cells/μl for two consecutive days. The MTD for patients who had not received any prior chemotherapy and who had received either no radiotherapy or radiotherapy confined to the cranium was 2.0 g/m² daily for two doses. The MTD for patients previously treated with chemotherapy or neuraxis radiotherapy was also 2.0 g/m² daily for two doses. Responses were seen in patients with medulloblastoma (8/9), glioblastoma multiforme (2/13), germinoma (1/1), and pineoblastoma (1/2). © 1995 Wi1ey‐Liss Inc.

Original language	English (US)
Pages (from-to)	241-247
Number of pages	7
Journal	Medical and Pediatric Oncology
Volume	24
Issue number	4
DOIs	https://doi.org/10.1002/mpo.2950240406
State	Published - Apr 1995

Keywords

CNS tumor
Sagramostim
cyclophosphamide

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Oncology
Cancer Research

Access to Document

10.1002/mpo.2950240406

Cite this

Lachance, D. H., Oette, D., Schold, S. C., Brown, M., Kurtzberg, J., Graham, M. L., Tien, R., Felsberg, G., Colvin, O. M., Moghrabi, A., Browning, I., Hockenberger, B., Stewart, E., Ferrell, L., Kerby, T., Duncan‐Brown, M., Golembe, B., Fuchs, H., Fredericks, R., ... Friedman, H. S. (1995). Dose escalation trial of cyclophosphamide with sargramostim in the treatment of central nervous system (CNS) neoplasms. Medical and Pediatric Oncology, 24(4), 241-247. https://doi.org/10.1002/mpo.2950240406

Lachance, DH, Oette, D, Schold, SC, Brown, M, Kurtzberg, J, Graham, ML, Tien, R, Felsberg, G, Colvin, OM, Moghrabi, A, Browning, I, Hockenberger, B, Stewart, E, Ferrell, L, Kerby, T, Duncan‐Brown, M, Golembe, B, Fuchs, H, Fredericks, R, Hayes, FA, Rubin, AS, Bigner, DD & Friedman, HS 1995, 'Dose escalation trial of cyclophosphamide with sargramostim in the treatment of central nervous system (CNS) neoplasms', Medical and Pediatric Oncology, vol. 24, no. 4, pp. 241-247. https://doi.org/10.1002/mpo.2950240406

@article{bc52b0795eb14387a772fe936a05513b,

title = "Dose escalation trial of cyclophosphamide with sargramostim in the treatment of central nervous system (CNS) neoplasms",

abstract = "We conducted a dose escalation trial of cyclophosphamide plus Sargramostim in the therapy of patients with newly diagnosed or recurrent central nervous system tumors. Cyclophosphamide was administered at doses ranging between 1.0 and 2.5 g/m2 daily for two doses. Sargramostim was administered at a fixed dose of 250 μg/m2 subcutaneously twice a day beginning 24 hours after the second cyclophosphamide dose and continuing through the leukocyte nadir until the absolute neutrophil count (ANC) was >1,000 cells/μl for two consecutive days. The MTD for patients who had not received any prior chemotherapy and who had received either no radiotherapy or radiotherapy confined to the cranium was 2.0 g/m2 daily for two doses. The MTD for patients previously treated with chemotherapy or neuraxis radiotherapy was also 2.0 g/m2 daily for two doses. Responses were seen in patients with medulloblastoma (8/9), glioblastoma multiforme (2/13), germinoma (1/1), and pineoblastoma (1/2). {\textcopyright} 1995 Wi1ey‐Liss Inc.",

keywords = "CNS tumor, Sagramostim, cyclophosphamide",

author = "Lachance, {Daniel H.} and Dagmar Oette and Schold, {S. Clifford} and Mark Brown and Joanne Kurtzberg and Graham, {Michael L.} and Robert Tien and Gary Felsberg and Colvin, {O. Michael} and Albert Moghrabi and Iley Browning and Beverly Hockenberger and Elizabeth Stewart and Lee Ferrell and Tracy Kerby and Margaret Duncan‐Brown and Barry Golembe and Herb Fuchs and Ruth Fredericks and Hayes, {Frances Ann} and Rubin, {Abbe Sue} and Bigner, {Darell D.} and Friedman, {Henry S.}",

year = "1995",

month = apr,

doi = "10.1002/mpo.2950240406",

language = "English (US)",

volume = "24",

pages = "241--247",

journal = "Medical and Pediatric Oncology",

issn = "0098-1532",

publisher = "Wiley-Liss Inc.",

number = "4",

}

TY - JOUR

T1 - Dose escalation trial of cyclophosphamide with sargramostim in the treatment of central nervous system (CNS) neoplasms

AU - Lachance, Daniel H.

AU - Oette, Dagmar

AU - Schold, S. Clifford

AU - Brown, Mark

AU - Kurtzberg, Joanne

AU - Graham, Michael L.

AU - Tien, Robert

AU - Felsberg, Gary

AU - Colvin, O. Michael

AU - Moghrabi, Albert

AU - Browning, Iley

AU - Hockenberger, Beverly

AU - Stewart, Elizabeth

AU - Ferrell, Lee

AU - Kerby, Tracy

AU - Duncan‐Brown, Margaret

AU - Golembe, Barry

AU - Fuchs, Herb

AU - Fredericks, Ruth

AU - Hayes, Frances Ann

AU - Rubin, Abbe Sue

AU - Bigner, Darell D.

AU - Friedman, Henry S.

PY - 1995/4

Y1 - 1995/4

N2 - We conducted a dose escalation trial of cyclophosphamide plus Sargramostim in the therapy of patients with newly diagnosed or recurrent central nervous system tumors. Cyclophosphamide was administered at doses ranging between 1.0 and 2.5 g/m2 daily for two doses. Sargramostim was administered at a fixed dose of 250 μg/m2 subcutaneously twice a day beginning 24 hours after the second cyclophosphamide dose and continuing through the leukocyte nadir until the absolute neutrophil count (ANC) was >1,000 cells/μl for two consecutive days. The MTD for patients who had not received any prior chemotherapy and who had received either no radiotherapy or radiotherapy confined to the cranium was 2.0 g/m2 daily for two doses. The MTD for patients previously treated with chemotherapy or neuraxis radiotherapy was also 2.0 g/m2 daily for two doses. Responses were seen in patients with medulloblastoma (8/9), glioblastoma multiforme (2/13), germinoma (1/1), and pineoblastoma (1/2). © 1995 Wi1ey‐Liss Inc.

AB - We conducted a dose escalation trial of cyclophosphamide plus Sargramostim in the therapy of patients with newly diagnosed or recurrent central nervous system tumors. Cyclophosphamide was administered at doses ranging between 1.0 and 2.5 g/m2 daily for two doses. Sargramostim was administered at a fixed dose of 250 μg/m2 subcutaneously twice a day beginning 24 hours after the second cyclophosphamide dose and continuing through the leukocyte nadir until the absolute neutrophil count (ANC) was >1,000 cells/μl for two consecutive days. The MTD for patients who had not received any prior chemotherapy and who had received either no radiotherapy or radiotherapy confined to the cranium was 2.0 g/m2 daily for two doses. The MTD for patients previously treated with chemotherapy or neuraxis radiotherapy was also 2.0 g/m2 daily for two doses. Responses were seen in patients with medulloblastoma (8/9), glioblastoma multiforme (2/13), germinoma (1/1), and pineoblastoma (1/2). © 1995 Wi1ey‐Liss Inc.

KW - CNS tumor

KW - Sagramostim

KW - cyclophosphamide

UR - http://www.scopus.com/inward/record.url?scp=0028960661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028960661&partnerID=8YFLogxK

U2 - 10.1002/mpo.2950240406

DO - 10.1002/mpo.2950240406

M3 - Article

C2 - 7700169

AN - SCOPUS:0028960661

SN - 0098-1532

VL - 24

SP - 241

EP - 247

JO - Medical and Pediatric Oncology

JF - Medical and Pediatric Oncology

IS - 4

ER -

Dose escalation trial of cyclophosphamide with sargramostim in the treatment of central nervous system (CNS) neoplasms

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this